Intravitreal injection of bevacizumab (Avastin) has revolutionized the treatment of diabetic eye disease, and has emerged as an important treatment modality, either as primary or adjuvant therapy for diabetic macular edema and proliferative diabetic retinopathy.
Vascular endothelial growth factor (VEGF) is a major driving force in the development of diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR). Intravitreal injection of the anti-VEFG medication bevacizumab (Avastin) has revolutionized the treatment of diabetic eye disease, and has emerged as an important treatment modality, either as primary or adjuvant therapy for DME and PDR.
The reference Avastin was approved to treat cancer, as was its biosimilar (Mvasi), but its off-label use to treat diabetic retinopathy remains popular and widespread around the world, especially in low-income countries, given its lower cost, perceived effectiveness, and comparable safety profile.
Writing for the Pan-American Collaborative Retina Study Group (PACORES), J. Fernando Arevalo, MD, and T.Y. Alvin Liu, MD, reviewed 5 years of experience using intravitreal bevacizumab for diabetic retinopathy in Latin America and Spain, and conclude that it is an important tool in the armamentarium for treating the complications of diabetic retinopathy.
The researchers add that intravitreal bevacizumab can also be used as a preoperative, adjuvant therapy before vitrectromy for proliferative diabetic retinopathy. Their study provides one of the longest-term follow-up data sets on the efficacy of the anti-VEGF treatments in DME. The review is published in the December 2017 issue of Asia-Pacific Journal of Ophthalmology (Philadelphia).
Their study enrolled 201 patients (296 eyes) with center-involving DME and vision loss who were treated monthly with 1.25 mg of intravitreal bevacizumab until edema was stabilized, then returned to clinic and treated on an as-needed regimen, based on best corrected visual acuity (BCVA) and optical coherence tomography (OCT). The main outcome measures were changes in BCVA and central macular thickness (CMT) at the 60-month follow-up visit.
The group’s data on preoperative intravitreal bevacizumab suggest that it is beneficial before vitrectomy for PDR, as it tends to decrease intraoperative bleeding, facilitate intraoperative fibroproliferative membrane dissection, and decrease postoperative bleeding. The researchers believe intravitreal bevacizumab before vitrectomy is safe, especially with careful planning and patient selection.
“Based on our experience, we recognize intravitreal bevacizumab to be an important tool in our armamentarium for treating the complications of diabetic retinopathy,” they conclude. “For center-involving DME, our real-world data suggest that there is a roughly 70% chance of stabilized or improved vision with intravitreal bevacizumab treatments over a time course of 5 years,” they write, adding that for PDR, intravitreal bevacizumab is a good adjuvant therapy for patients who have already received prior panretinal photocoagulation treatment. Finally, they conclude that preoperative intravitreal bevacizumab before vitrectromy is safe, with a low incidence of development or progression of tractional retinal detachment.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Eye on Pharma: Canadian Aflibercept Settlement; Sandoz Acquires Cimerli; Payer Chooses Cyltezo
March 6th 2024Biocon Biologics settled with the maker of Eylea (aflibercept), announcing a launch date for its biosimilar competitor in Canada; Sandoz has officially acquired Cimerli, a ranibizumab biosimilar; AARP Medicare Rx from United Healthcare has added Cyltezo (adalimumab-adbm) and removed the originator (Humira) from its formulary.